Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAetna romiplostim (Nplate) Coverage & Prior Auth |…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0768

    Romiplostim (Nplate) coverage

    Customize your policy alerts

    Sign up for Aetna Policy 0768 alerts

    Get alerted when Policy 0768 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Aetna commercial medical plan coverage and medical necessity criteria for romiplostim (Nplate) across specified indications (ITP, HS-ARS, MDS, chemotherapy-induced thrombocytopenia) and prescriber requirements.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyRomiplostim (Nplate) coverage
    Policy CodePolicy 0768
    Change TypeNo material changes
    Effective DateNov 7, 2008
    Last ReviewJan 9, 2024
    Next Review DateAug 22, 2024
    Key ActionObtain prior authorization demonstrating medical necessity and document prior inadequate response to corticosteroids, IVIG, or splenectomy for chronic ITP.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    FDA-approved for ITP & HS-ARSRegulatory indications discussed
    4Covered indications listed
    J2796HCPCS code
    1–10 mcg/kgRecommended dosing range
    46%Durable response in MDS trial
    >=14References

    Medical Necessity and Coverage Criteria

    inv-01: Initial Therapy — ITP

    Covered when the following criteria are met

    Immune Thrombocytopenia (ITP) - Initial Approval: Both: 1) Inadequate response or intolerance to prior therapy with corticosteroids, immunoglobulins, or splenectomy; AND 2) Untransfused platelet count at any point prior to initiation < 30 x 10^9/L, OR platelet count at diagnosis 30–50 x 10^9/L with symptomatic bleeding or risk factors for bleeding.see platelet thresholds

    Prescribed by or in consultation with a hematologist or oncologist

    inv-02: Initial Therapy — HS-ARS

    Covered when the following criteria are met

    Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS): Treatment of HS-ARS (acute exposure to myelosuppressive doses of radiation).Nplate dose 10 mcg/kg administered once as soon as possible after suspected/confirmed exposure >2 Gy

    Applies to adults and pediatrics including term neonates; FDA approval under Animal Rule

    inv-03: Initial/Continuation Therapy — MDS

    Covered when the following criteria are met

    Myelodysplastic Syndromes (MDS): Romiplostim may be used for treatment of MDS (compendial/off-label use); continuation requires documented benefit such as increased platelet counts, decreased bleeding events, or reduced need for platelet transfusions.

    Monitor for increased blast counts and potential progression to AML; use generally limited to lower‑risk MDS and select patients with refractory bleeding/transfusion dependence

    inv-04: Initial and Continuation Therapy — CIT

    Covered when the following criteria are met

    Chemotherapy-Induced Thrombocytopenia (CIT) - Initial Approval: Either: 1) Platelet count < 100 x 10^9/L for at least 3–4 weeks following the last chemotherapy administration; OR 2) Chemotherapy administration has been delayed due to thrombocytopenia.

    Compendial/off-label use supported by small series reporting weekly initiation at 1–2 µg/kg with escalation to platelet targets

    Chemotherapy-Induced Thrombocytopenia (CIT) - Continuation: All: 1) Member is experiencing benefit from therapy (increased platelet counts, decreased bleeding events, reduced need for platelet transfusions) to maintain a target platelet count of 100–200 x 10^9/L; AND 2) Therapy is being used to maintain chemotherapy dose schedule and intensity.

    Continuation supports ongoing coverage when objective benefit is documented

    inv-05: Continuation Therapy — ITP

    Covered when any of the following continuation conditions are met

    ITP - Continuation Criteria: One of: 1) Current platelet < 50 x 10^9/L and platelet insufficient to prevent clinically important bleeding and member has not received maximal Nplate dose for ≥4 weeks; OR 2) Current platelet < 50 x 10^9/L but sufficient to prevent clinically important bleeding; OR 3) Current platelet 50–200 x 10^9/L; OR 4) Current platelet >200 to ≤400 x 10^9/L for whom dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding.

    Continuation rules specify dose adjustments and monitoring per dosing guidance

    inv-06: FDA-approved indications

    Covered when ALL of the following are met

    FDA-approved indications: Patient has chronic immune thrombocytopenia (ITP) with insufficient response to corticosteroids, immunoglobulins, or splenectomy, OR patient meets FDA criteria for HS-ARS (acute radiation exposure).

    FDA-approved indications supported by prescribing information and Animal Rule approval for HS-ARS

    inv-07: Myelodysplastic syndromes (selective use)

    Use may be considered (off-label) when ALL of the following are met

    MDS (select lower‑risk cases): Patient has lower‑risk MDS (eg, IPSS low or intermediate‑1 / IPSS‑R very low/low/intermediate) with clinically significant bleeding or refractory thrombocytopenia despite transfusions and supportive measures.

    Randomized trial showed platelet increases and reduced bleeding/transfusions but was discontinued early due to concerns about blasts/AML; long‑term follow‑up did not show significant increase in AML or death—use limited to select patients after risk/benefit discussion

    inv-08: Chemotherapy-induced thrombocytopenia (investigational/off-label)

    Consider when ALL of the following are met

    Chemotherapy‑induced thrombocytopenia (CIT): Patient has dose‑limiting, chemotherapy‑induced thrombocytopenia with prior failure to recover and the treating clinician intends romiplostim to enable continuation of cytotoxic chemotherapy.

    Evidence consists of small retrospective series showing platelet recovery and ability to resume chemotherapy; prospective trials needed

    inv-09: Aplastic anemia (limited evidence)

    Consider when ALL of the following are met

    Aplastic anemia: Use in severe aplastic anemia after failure of eltrombopag or as adjunct with immunosuppressive therapy in select cases has case‑series/supportive reports of responses; consider only in specialized settings.

    Evidence is limited to small case series and reports; further study required

    inv-10: Indications and evidence summaries

    Clinical indications and evidence summaries present in this section

    Approved indication: Romiplostim is FDA‑approved for chronic immune thrombocytopenia (ITP) in adults and pediatric patients ≥1 year with insufficient response to corticosteroids, immunoglobulins, or splenectomy.

    Supported by prescribing information and randomized trials

    MDS‑related thrombocytopenia: Romiplostim is not FDA‑approved for thrombocytopenia due to MDS; randomized trial (n=250) in lower‑risk MDS showed platelet increases but was discontinued early due to potential AML progression concerns; 5‑year follow‑up did not show significant differences in AML or death.

    Use in MDS is off‑label and evidence is limited

    Pediatric use: In children with chronic ITP, romiplostim is an effective second‑line therapy; guidelines generally recommend exhausting medical options before splenectomy.

    FDA‑approved for pediatric ITP ≥1 year

    Concomitant use of romiplostim with other thrombopoietin receptor agonists (for example, eltrombopag, avatrombopag, or lusutrombopag) or with spleen tyrosine kinase inhibitors (e.g., Tavalisse) is excluded and will not be covered. This medication must be prescribed by or in consultation with a hematologist or oncologist; requests that indicate concurrent use with the agents listed above should be denied as not eligible for coverage under this policy.

    Romiplostim is not indicated by the FDA for treatment of thrombocytopenia due to myelodysplastic syndromes (MDS) or for any cause of thrombocytopenia other than chronic immune thrombocytopenia (ITP). The FDA review of early MDS experience reported possible disease progression in a subset of patients and concluded that randomized controlled studies are needed to define risks and benefits; therefore use for MDS is not an FDA-approved indication.

    Use of romiplostim in MDS is considered off-label/compendial. Randomized studies in lower-risk MDS showed increases in platelet counts and reductions in bleeding events, but early discontinuation of the trial due to concerns about progression to acute myelogenous leukemia (AML) limits interpretation. Long-term follow-up data did not demonstrate a significant increase in AML or death, but romiplostim remains not FDA-approved for MDS and any use should be limited to selective situations with careful monitoring (for example, documented clinical benefit and surveillance for rising blast counts).

    Aetna considers romiplostim experimental and investigational (not medically necessary) for indications where effectiveness has not been established, including: aplastic anemia, Evans syndrome, graft-versus-host disease, hepatitis C, stem cell mobilization, thrombocytopenia during pregnancy, and thrombocytopenia following allogeneic stem cell transplantation. Requests for these indications should be treated as investigational unless compelling evidence from peer-reviewed sources and compendia justify coverage.

    Routine use of romiplostim in MDS is not supported. The FDA and guideline authors note that while some trials demonstrated platelet responses, early trial discontinuation over safety concerns and limited evidence mean romiplostim should not be used routinely in MDS. Consideration may be appropriate only for selected lower-risk patients with clinically significant bleeding refractory to transfusions and antifibrinolytics, and where the potential benefits outweigh the risks.

    Specifically for romiplostim in MDS, routine use is not recommended based on the randomized trial in low/intermediate-1 risk patients that was stopped early for concern about leukemic progression. Although 5-year follow-up did not show a significant increase in AML or mortality, romiplostim remains an off-label option for MDS and should generally be reserved for select patients with refractory bleeding or transfusion dependence and only with close monitoring for blast increases.

    Dosing, Administration, and Regimens

    RegimenDetailsCoverage status
    {"text":"Initial dosing","status":""},{"text":"Start romiplostim 1 mcg/kg subcutaneously once weekly; adjust weekly by 1 mcg/kg increments based on platelet response to achieve and maintain platelet count ≥50 × 10^9/L; maximum weekly dose 10 mcg/kg.","status":""},{"text":"Covered","status":"covered"}
    {"text":"Dose escalation","status":""},{"text":"If platelet count <50 × 10^9/L, increase dose by 1 mcg/kg weekly until target achieved (not to exceed 10 mcg/kg/week).","status":""},{"text":"Covered","status":"covered"}
    {"text":"Dose reduction","status":""},{"text":"If platelet count >200 to ≤400 × 10^9/L for 2 consecutive weeks, reduce dose by 1 mcg/kg. If platelet count >400 × 10^9/L, hold dosing; resume at dose reduced by 1 mcg/kg after count falls to <200 × 10^9/L.","status":""},{"text":"Covered","status":"covered"}
    {"text":"Maximum duration criteria","status":""},{"text":"Discontinue if platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximum weekly dose of 10 mcg/kg.","status":""},{"text":"Covered","status":"covered"}
    RegimenDetailsCoverage status
    {"text":"HS-ARS single-dose regimen","status":""},{"text":"Administer a single subcutaneous injection of romiplostim 10 mcg/kg as soon as possible after suspected or confirmed exposure to radiation >2 Gy (applies to adults and pediatrics, including term neonates).","status":""},{"text":"Covered","status":"covered"}
    RegimenDetails / institutional experienceCoverage status
    {"text":"Supportive CIT regimen (reported series)","status":""},{"text":"Weekly subcutaneous romiplostim initiated at 1–3 μg/kg with escalation (commonly by 1 μg/kg weekly) to achieve platelet targets (eg, ≥100 × 10^9/L in cited series); in Memorial Sloan-Kettering series mean dose to recovery ~2.9 μg/kg (range 1.0–5.1 μg/kg); weekly dosing continued during chemotherapy to permit on-schedule treatment.","status":""},{"text":"Experimental","status":"experimental"}
    RegimenDetails / trial dosing and outcomesCoverage status
    {"text":"MDS trial dosing (varied)","status":""},{"text":"Weekly romiplostim studied in lower‑risk MDS with varied fixed doses; early studies used cohorts receiving 300, 700, 1,000, or 1,500 μg weekly and other studies evaluated 750 μg weekly subcutaneously; extension phases allowed up to 1 year of treatment.","status":""},{"text":"Experimental","status":"experimental"}
    {"text":"Safety signal and follow-up","status":""},{"text":"A randomized trial (n=250) was halted early because of concern for increased blasts/possible AML progression; a 5‑year follow-up found no significant difference in AML (12% romiplostim vs 11% placebo) or death.","status":""},{"text":"Experimental","status":"experimental"}
    RegimenDetails / evidence summaryCoverage status
    {"text":"Clinical trial exposure duration","status":""},{"text":"Romiplostim has been administered in clinical trials for MDS-related thrombocytopenia for up to 58 weeks (randomized study) and in extension phases up to ~1 year; evidence is limited and interpretation affected by early discontinuation of drug in pivotal trial.","status":""},{"text":"Experimental","status":"experimental"}
    {"text":"Regulatory/approval status for MDS","status":""},{"text":"Romiplostim is not FDA-approved for treatment of thrombocytopenia due to myelodysplastic syndromes; use in MDS is off-label and may be considered selectively with monitoring for blast increases.","status":""},{"text":"Not covered (routine)","status":"not_covered"}
    Regimen / indicationPopulation / labelingCoverage status
    {"text":"Chronic immune thrombocytopenia (ITP)","status":""},{"text":"FDA-approved for adults and pediatric patients 1 year of age and older with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; dosing as per ITP recommendations (start 1 mcg/kg weekly with adjustments).","status":""},{"text":"Covered","status":"covered"}

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J2796Injection, romiplostim, 10 mcg [Nplate]
    Covered ICD-10 Codes (examples)ICD-10Covered
    D69.3Immune thrombocytopenic purpura [idiopathic]
    D69.59Other secondary thrombocytopenia [chemotherapy-induced thrombocytopenia]
    D46.22Myelodysplastic syndrome
    T66.XXXARadiation sickness, unspecified [Hematopoietic syndrome of acute radiation syndrome]
    ICD-10 Codes Not Covered / Experimental IndicationsICD-10Not Covered
    B17.10Acute hepatitis C
    D61.01Other aplastic anemias and other bone marrow failure syndromes
    T86.5Complications of stem cell transplant [thrombocytopenia following allogeneic stem cell transplantation]
    Platelet count thresholds for ITP
    Initial platelet thresholdUntransfused platelet count < 30 x 10^9/L prior to initiation (or platelet count 30–50 x 10^9/L at diagnosis with symptomatic bleeding or bleeding risk).
    Continuation — insufficient plateletCurrent platelet < 50 x 10^9/L and platelet insufficient to prevent clinically important bleeding, with member not having received maximal Nplate dose for ≥4 weeks.
    Continuation — low but adequateCurrent platelet < 50 x 10^9/L where the platelet count is sufficient to prevent clinically important bleeding.
    Continuation — target rangeCurrent platelet count 50 x 10^9/L to 200 x 10^9/L (acceptable for continuation).
    Continuation — high range requiring adjustmentCurrent platelet > 200 x 10^9/L to ≤ 400 x 10^9/L for whom dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding.

    Prior Authorization, Documentation, and Prescriber Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for romiplostim (HCPCS J2796).

    • Prior authorization required for romiplostim (J2796).
    • Prescriber specialty: must be prescribed by or in consultation with a hematologist or oncologist.
    • Exclusion: Do not use concomitantly with other TPO-RAs (eltrombopag, avatrombopag, lusutrombopag) or spleen tyrosine kinase inhibitors (e.g., fostamatinib/Tavalisse).
    Prior Authorization

    Prior Authorization — Non‑ITP Indications

    Prior authorization applies to non-ITT indications (e.g., MDS, HS-ARS, chemotherapy-induced thrombocytopenia) and these uses may be subject to additional review; MDS use is off-label and carries safety/denial risk.

    • Prior authorization required for non-ITP indications (MDS, HS-ARS, CIT).
    • MDS use: randomized data limited; safety concerns (potential for progression to AML) — may be denied or require detailed justification and risk/benefit documentation.

    Therapy Line and Salvage Use

    inv-42: salvage — line-of-therapy criterion (top-level node)

    salvage: Romiplostim used for MDS per compendial use; continuation requires documented benefit (increased platelets, decreased bleeding, reduced transfusions).

    Monitor for blast increases and risk of AML progression.

    inv-43: salvage — line-of-therapy criterion (top-level node)

    salvage: Supportive therapy during chemotherapy: used to manage dose‑limiting chemotherapy‑induced thrombocytopenia to allow continuation of systemic chemotherapy; typically given weekly with dose titration.

    Evidence from small series supports platelet recovery and chemotherapy continuation

    inv-44: salvage — line-of-therapy criterion (top-level node)

    Drug Background and Definitions

    Romiplostim is a thrombopoiesis-stimulating peptibody that binds the thrombopoietin receptor to increase platelet production. It is FDA-approved for treatment of chronic immune thrombocytopenia (ITP) in adults and pediatric patients ≥1 year with insufficient response to corticosteroids, immunoglobulins, or splenectomy, and was granted approval under the Animal Rule to increase survival after acute high-dose radiation exposure (hematopoietic syndrome of acute radiation syndrome, HS-ARS). Key safety considerations noted in the literature include potential thrombotic events with platelet increases, loss of response possibly due to neutralizing antibodies or marrow fibrosis, and concerns about leukemic progression when used in MDS populations.

    HS-ARS definition and indication context
    DefinitionHematopoietic syndrome of acute radiation syndrome (HS-ARS): acute exposure to myelosuppressive doses of radiation causing life‑threatening cytopenias for which romiplostim is indicated to increase survival.
    Regulatory contextFDA approved (Jan 28, 2021) under the Animal Rule to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation.
    Dosing contextRecommended single subcutaneous injection of romiplostim 10 mcg/kg administered as soon as possible after suspected or confirmed exposure >2 Gy.

    Policy History, References, and Administrative Data

    Note

    Prior authorization — policy history/administrative info

    The policy history section provides review dates and links to history and definitions but does not add prescriptive prior authorization steps.

    • Refer to the policy main criteria for required actions; history page is informational.

    Selected references that inform this policy include clinical trials and reviews of romiplostim use in ITP and MDS, FDA materials, and specialty literature. Notable citations include the FDA approval summary and related materials, randomized and long-term follow-up studies in MDS, and reviews on management of chemotherapy-induced thrombocytopenia and pediatric use (see full reference list for details).

    Policy Summary
    PayerAetna
    PolicyRomiplostim (Nplate) coverage
    Policy CodePolicy 0768
    Change TypeNo material changes
    Effective DateNov 7, 2008
    Last ReviewJan 9, 2024
    Next Review DateAug 22, 2024
    Key ActionObtain prior authorization demonstrating medical necessity and document prior inadequate response to corticosteroids, IVIG, or splenectomy for chronic ITP.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaDosing, Administration, and RegimensBilling and CodingPrior Authorization, Documentation, and Prescriber RequirementsTherapy Line and Salvage UseDrug Background and DefinitionsPolicy History, References, and Administrative Data
    Pregnancy: Limited case reports suggest romiplostim may be used for corticosteroid‑refractory ITP in pregnancy without reported fetal or maternal complications; further data are needed.

    Evidence limited to case reports and reviews

    Post‑allogeneic HSCT and therapy‑related thrombocytopenia: Small case series and retrospective reports suggest romiplostim can induce platelet recovery after HSCT and in therapy‑related thrombocytopenia, but randomized data are lacking.

    Further prospective studies required

    Prior Authorization

    Prior Authorization — Chronic ITP (FDA‑approved criteria)

    Prior authorization is required for chronic ITP and will follow FDA‑approved criteria: inadequate response or intolerance to corticosteroids, IVIG, or splenectomy and platelet count thresholds or symptomatic bleeding as specified in policy.

    • ITP prerequisites: documentation of inadequate response or intolerance to corticosteroids, immunoglobulins (IVIG), or splenectomy.
    • Platelet criteria: untransfused platelet count < 30 x 10^9/L prior to initiation, or 30–50 x 10^9/L at diagnosis with symptomatic bleeding or bleeding risk factors.
    Denial Risk

    Denial Risk — Indication and MDS Safety Concerns

    Use may be denied when the indication is not supported (e.g., thrombocytopenia due to causes other than chronic ITP) or when required prior‑therapy criteria are not met.

    • Indication‑based denial risk: use for MDS or non‑ITP causes may be denied without documentation of medical necessity.
    • Off‑label MDS risk: randomized evidence limited and early studies signaled potential leukemic progression — expect heightened review and possible denial for MDS without strong justification.
    Documentation Required

    Documentation Required

    Required clinical documentation should be submitted with the authorization request to support medical necessity.

    • Diagnosis and relevant ICD‑10 code.
    • For ITP: prior therapies tried (corticosteroids, IVIG, splenectomy) with dates and clinical response or intolerance.
    • Baseline and recent platelet counts (untransfused) and description of bleeding symptoms or bleeding‑risk factors if platelets 30–50 x 10^9/L.
    • For MDS: diagnosis plus IPSS/IPSS‑R risk classification and rationale for use given limited approval status.
    • Medication history to confirm no concomitant TPO‑RAs or spleen tyrosine kinase inhibitors.
    Step Therapy

    Step Therapy and Pediatric Context

    Step therapy: romiplostim for ITP is reserved for patients with inadequate response or intolerance to prior therapies; however, no additional formal step limits (e.g., mandatory trial of splenectomy before use) are imposed beyond the listed prior‑therapy criteria and pediatric context.

    • Step therapy for ITP: require inadequate response or intolerance to corticosteroids, IVIG, or splenectomy prior to romiplostim.
    • Context: FDA labeling specifies prior use/insufficient response to corticosteroids, IVIG, or splenectomy.
    • Pediatric context: guidelines favor exhausting medical therapies (corticosteroids, IVIG, TPO‑RAs) before splenectomy; splenectomy generally deferred ≥12 months of ITP.
    Note

    Policy History and Administrative Links

    Administrative and policy history resources: include review history, last review date, and links for definitions and review pages as part of provider resources.

    • Policy effective date: 11/07/2008; Next review: 08/22/2024.
    • Last review: 01/09/2024; Review history and definitions available via Aetna policy links.
    salvage: Consideration of romiplostim in MDS: limited to lower‑risk MDS with bleeding refractory to transfusions and antifibrinolytic therapy; not routine therapy due to safety concerns from trials.

    Selection should be case‑by‑case after risk/benefit assessment

    Chronic ITP definition
    DefinitionChronic immune thrombocytopenia (ITP): immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins, or splenectomy where thrombocytopenia and clinical condition increase bleeding risk.
    PopulationIncludes adults and pediatric patients ≥1 year of age (per FDA labeling) with chronic ITP and inadequate response to first‑line therapies.
    Therapeutic intentRomiplostim is intended to reduce bleeding risk rather than to normalize platelet counts.
    HS-ARS alternate definition (severity)
    Alternate/Severity definitionHS-ARS refers to the hematopoietic syndrome from acute, myelosuppressive radiation exposure that causes life‑threatening cytopenias; severity is sufficient to warrant interventions to increase survival (eg, romiplostim).
    Evidence basisApproval and severity determination were based on animal efficacy studies and supporting human safety data, because human efficacy studies are not feasible or ethical.
    Affected populationsApplies to adults and pediatric patients, including term neonates, exposed acutely to myelosuppressive radiation doses (>2 Gy).
    MDS prognostic scoring systems (IPSS/IPSS-R/WPSS) definition
    IPSSInternational Prognostic Scoring System (IPSS): a tool using prognostic indicators to assign risk groups and guide treatment approach in MDS.
    IPSS-RRevised International Prognostic Scoring System (IPSS-R): more detailed assessment of the same disease factors as IPSS for MDS risk stratification.
    WPSSWHO classification-based Prognostic Scoring System (WPSS): incorporates MDS subtype and presence/absence of severe anemia as prognostic factors; less commonly used than IPSS/IPSS-R.
    PurposeThese scoring systems classify MDS risk (eg, lower‑risk vs higher‑risk) to inform prognosis and treatment decisions, including consideration of romiplostim in select lower‑risk cases.